Nicholas Butowski

MD

Neuro-oncologist
Avid football – also known as soccer – fan

About me

Dr. Nicholas Butowski is a neuro-oncologist who specializes in brain tumors, neuroimaging, cognitive and rehabilitative neurology, and complementary therapies for neurological disorders. He is director of clinical services in neuro-oncology and a researcher at the Brain Tumor Center.

In his research, Butowski focuses on developing treatments for primary brain tumors as well as methods to ensure good quality of life for patients and to assist them in recovering from or coping with brain injury.

Butowski earned his medical degree at the University of Illinois at Chicago. He completed a residency in neurology and a fellowship in neuro-oncology at UCSF. He is a member of the American Academy of Neurology, American Society of Clinical Oncology and Society for Neuro-oncology.

  • Education

    University of Illinois College of Medicine, 1999

  • Residencies

    UCSF Medical Center, Neurology, 2003

  • Fellowships

    UCSF Medical Center, Neuro-oncology, 2004

  • Academic Title

    Professor

Compassion is not a virtue; it is a commitment.

Conditions I specialize in

Brain Tumor Center

400 Parnassus Ave., Eighth Floor
San Francisco, CA 94143

(415) 353-2966
M-F, 8 a.m. - 5 p.m.
Decorative Caduceus

Vigilant ObservatIon of GlIadeL WAfer ImplaNT Registry

This is a prospective, observational registry in patients who have been prescribed Gliadel Wafer by the physician as part of usual care.

Recruiting

Decorative Caduceus

ONC201 in Adults With Recurrent H3 K27M-mutant Glioma

The primary objective of this phase II trial is to determine the efficacy and safety of ONC201, an oral small molecule imipridone DRD2 antagonist, in adult subjects with recurrent high-grade glioma. This study will t...

Recruiting

Decorative Caduceus

A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies

This is a Phase 1, open-label, first-in-human (FIH) dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary antitumor activity of DCC-2618, ad...

Recruiting

Decorative Caduceus

A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade...

This is a pilot, randomized, two arm neoadjuvant vaccine study in human leukocyte antigen-A2 positive (HLA-A2+) adults with World Health Organization (WHO) grade II glioma, for which surgical resection of the tumor i...

Recruiting

Contact me

Providers on my team

Share